Why the study?
COVID-19 is highly contagious and targeted antiviral therapy remains premature and largely unknown, making the management of AF patients during the pandemic particularly challenging.
This review provides early pandemic-era guidance on the pathophysiological links and management of atrial fibrillation in patients with COVID-19.
AF management during COVID-19 remains challenging; leaves open optimal strategies pending higher-level evidence.
The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: